Global ePRO, E-Patient Diaries and eCOA Market to Reach US$2.8 Billion by the Year 2026

·25 min read

Abstract: Global ePRO, E-Patient Diaries and eCOA Market to Reach US$2. 8 Billion by the Year 2026 . ePRO, eCOA, and e-patient diaries are among the technologies that are enabling healthcare providers and clinical trial companies to enable electronic data capture and analysis.

New York, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global ePRO, E-Patient Diaries and eCOA Industry" - https://www.reportlinker.com/p05956727/?utm_source=GNW
Electronic Patient Reported Outcomes (ePROs) involve reporting of health outcomes directly to the patients in a seamless manner, while electronic outcome assessment (eCOA) involves the electronic capture of data during clinical trials, enables adherence to regulatory requirements, and improves the quality of study data. Growth in the global market is set to be fueled by increasing pressure on medical device, pharmaceutical and biotechnology companies for improving the productivity, reducing costs, and expediting the process of drug development. Growth in the market is also being driven by the continuous rise in demand for clinical trials and research studies to develop new drugs, therapies and vaccines. Specifically, the COVID-19 pandemic has led to increased focus by pharma companies and clinical study companies on development of new therapies, vaccines and drugs for managing COVID-19 infection. Faster trial implementation, real-time data sharing, and increased visibility became more relevant during the development of vaccines against SARS-CoV-2. Also, since there are more people using smartphones, therefore there is greater acceptability of eCOA and ePRO methods. However, need for Internet connectivity, lack of patient awareness about these advanced technologies and shortage of sufficiently skilled persons with technical know-how inhibit the growth and expansion of the market. Concerns about data privacy are another inhibiting factor, with technology advancements and clinical communication and collaborative solutions raise concerns about privacy and security.

Amid the COVID-19 crisis, the global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.8 Billion by 2026, growing at a CAGR of 14.3% over the analysis period. EClinical Outcome Assessments (eCOAs), one of the segments analyzed in the report, is projected to grow at a 14.6% CAGR to reach US$1.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the epatient Reported Outcomes (ePROs) segment is readjusted to a revised 15.9% CAGR for the next 7-year period. This segment currently accounts for a 21.6% share of the global ePRO, E-Patient Diaries and eCOA market. Growth in the eCOA market is being spurred by the increase in clinical trials being conducted, growth in R&D spending in pharma industry, rising prevalence of chronic diseases, and the growing need for real time data analysis. More emphasis on the patient reported outcomes as well as push towards the use of technology in clinical trials is resulting in massive growth in the use of ePRO. Another factor which is expected to propel the ePRO market in the coming years is the growing post-market research activity, which requires data to be collected for lifecycle management of patented drugs, reimbursement analyses, and safety evaluation.

The U.S. Market is Estimated at $501.3 Million in 2021, While China is Forecast to Reach $326.9 Million by 2026

The ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$501.3 Million in the year 2021. The country currently accounts for a 35.58% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$326.9 Million in the year 2026 trailing a CAGR of 17.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 13.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR while Rest of European market (as defined in the study) will reach US$387.2 Million by the end of the analysis period. Developed regions of North America and Europe account for a significant share of the market owing to rise in the number of clinical trials.

Clinician Reported Outcomes (ClinROs) Segment to Reach $441.5 Million by 2026

A Clinician Reported Outcome (ClinRO) refers to a report that is received from a healthcare professional based on observations of the patient`s health condition. The rise in electronic data capture and availability of better quality data, which is importance for clinical trials, presents lucrative opportunities for ClinRO. In the global Clinician Reported Outcomes (ClinROs) segment, USA, Canada, Japan, China and Europe will drive the 12.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$178 Million in the year 2020 will reach a projected size of US$413.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$47.8 Million by the year 2026.


Select Competitors (Total 49 Featured)

  • Anju Software, Inc.

  • ArisGlobal LLC

  • ERT Clinical

  • ICON plc

  • Kayentis, SAS

  • Medidata Solutions Inc.

  • Mednet

  • Signant Health




Read the full report: https://www.reportlinker.com/p05956727/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of COVID-19 Pandemic and Looming Global Recession
2020: A Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is
the World Economy Headed in 2021?
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual
% Change) for 2020 through 2022
Pandemic Jolt Brings Strategic & Lasting Changes to Healthcare
Sector
COVID-19 Expedites Healthcare Ecosystem?s Evolution for Better
Care & Cost Savings
The Adoption of Telemedicine Services Accelerates Amidst the
Pandemic
EXHIBIT 2: Telemedicine Leads Digital Health Investments Driven
by COVID-19: Leading Categories of Digital Health by Funding
(In US$ Million) for the Year 2020
EXHIBIT 3: Telehealth Visits in the US (In Million) for the
Years 2019 and 2020
EXHIBIT 4: Global Number of Telemedicine Patients (In Million)
for the Years 2016, 2018, 2020, 2023 & 2025
COVID-19 Outbreak Compels Clinical Trials Industry to Move
Towards ePRO
eCOA Solutions Help Address Hurdles Due to COVID-19 Pandemic
eCOA Playing a Part in Development of COVID-19 Vaccine
An Introduction to ePRO, E-Patient Diaries and eCOA
Global Market Prospects & Outlook
eCOA: The Largest Category
Competition
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Digitalization of Healthcare Services and Rising Importance of
Electronic Data Capture Technologies to Fuel Market Growth
EXHIBIT 5: Global Digital Health Market: Annual Sales in US$
Million by Geographic Region for 2020 and 2027
Growing Demand for Clinical Trials Drives Need for ePRO,
ePatient Diaries, and eCOA Solutions
EXHIBIT 6: Clinical Trials in the US: % Change in Trial Starts
by Therapy Area for 2020 Vs 2019
COVID-19 Pandemic Triggers Technology Adoption in Clinical Trials
EXHIBIT 7: Global Venture Funding (in $ Million) in Digital
Health Solutions Targeting Clinical Trials for 2015-2020
Shift Towards Decentralized/Virtual Clinical Trials to Boost
Market Prospects
EXHIBIT 8: Global Virtual Clinical Trials Market Size (in US$
Billion) for the Years 2020, 2022, 2024 and 2026
EXHIBIT 9: Global Virtual Clinical Trials Market by Indication
(in %) for 2020
Role of eCOA & ePRO in Enhancing Data Accuracy of Decentralized
Clinical Trials
Growing Volumes of Data Generation in Decentralized Trials:
A Challenge
Adoption of Digital Technologies in Contract Research
Organizations Bodes Well for the Market
EXHIBIT 10: Global Contract Research Outsourcing Market
Revenues (US$ Million) by Geographic Region for 2020 and 2027
EXHIBIT 11: Pharmaceutical R&D Spending Worldwide (USD Billion):
2015-2025
COVID-19 and Implications for Drug Development Regulations &
Processes
Advances in ePRO Technologies Promise Better Clinical Decision
Making in Healthcare Systems
Rise in Telemedicine Services Present Market Opportunities
EXHIBIT 12: Global Tele-Healthcare Market (In US$ Million) for
Years 2020, 2022, 2024 and 2026
Growing Adoption of Mobile Technologies and BYOD Trend in
Healthcare Industry Boosts Market Prospects
EXHIBIT 13: Smartphone Penetration Rate as Share of Total
Population: 2016-2021
EXHIBIT 14: Mobile Device Use in Healthcare Settings: % Usage
by Type of Mobile Device
Electronic Patient Record (ePRO) Solutions Emerge as Ideal
Replacements for Paper-Based PRO systems
Major Benefits of ePRO over Paper Form in Clinical Trials
Factors Ensuring Success ePRO Implementations
ePatient-Reported Outcomes (PROs) Gain Importance in Oncology
Studies
Key Technology Trends Impacting the ePRO in Clinical Trials
Data Integrity, Security & Privacy: Key Priorities for ePRO
Solutions
Electronic Clinical Outcome Assessment Solution (eCOA) Market:
Poised for Growth
EXHIBIT 15: Global e-COA Market by Delivery Mode (in %) for 2020
EXHIBIT 16: eCOA Usage by Clinical Trial Phase (in %) for 2020
Technological Trends Transforming eCOA Solutions Market
E-Patient Diaries: Significant Advantages over Paper Diaries to
Drive Market
Major Benefits of ePatient Diary
Increase in Healthcare Spending to Propel Demand
EXHIBIT 17: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
EXHIBIT 18: Spending as % of GDP by Country for 2019 and 2030
Increasing Burden of Chronic Diseases and Focus on Drug
Development, Therapies and Vaccines Boosts Market
EXHIBIT 19: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 20: Global Annual Medical Cost of CVD in US$ Billion:
(2010-2030)
EXHIBIT 21: Fatalities by Heart Conditions: Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others
EXHIBIT 22: World Diabetes and Population Statistics (2019,
2030 & 2045)
Aging World Population & COVID-19 Induced Re-Focus on Aging-In -
Place to Drive Market Growth
EXHIBIT 23: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 2: World 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2021 & 2027

Table 3: World Current & Future Analysis for EClinical Outcome
Assessments (eCOAs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 4: World 7-Year Perspective for EClinical Outcome
Assessments (eCOAs) by Geographic Region - Percentage Breakdown
of Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2021 & 2027

Table 5: World Current & Future Analysis for ePatient Reported
Outcomes (ePROs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 6: World 7-Year Perspective for ePatient Reported
Outcomes (ePROs) by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2021 & 2027

Table 7: World Current & Future Analysis for Clinician Reported
Outcomes (ClinROs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 8: World 7-Year Perspective for Clinician Reported
Outcomes (ClinROs) by Geographic Region - Percentage Breakdown
of Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2021 & 2027

Table 9: World Current & Future Analysis for ePatient Diaries
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 10: World 7-Year Perspective for ePatient Diaries by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 11: World Current & Future Analysis for Performance
Outcomes (PerfOs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 12: World 7-Year Perspective for Performance Outcomes
(PerfOs) by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2021 & 2027

Table 13: World Current & Future Analysis for Observer Reported
Outcomes (ObsROs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 14: World 7-Year Perspective for Observer Reported
Outcomes (ObsROs) by Geographic Region - Percentage Breakdown
of Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2021 & 2027

Table 15: World Current & Future Analysis for Clinical Trial
Sponsors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 16: World 7-Year Perspective for Clinical Trial Sponsors
by Geographic Region - Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 17: World Current & Future Analysis for Contract Research
Organizations (CROs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 18: World 7-Year Perspective for Contract Research
Organizations (CROs) by Geographic Region - Percentage
Breakdown of Value Revenues for USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World for Years 2021 & 2027

Table 19: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 20: World 7-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2021 & 2027

Table 21: World Current & Future Analysis for Academic
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 22: World 7-Year Perspective for Academic Institutes by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 23: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 24: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 26: USA 7-Year Perspective for ePRO, ePatient Diaries and
eCOA by Solution Type - Percentage Breakdown of Value Revenues
for EClinical Outcome Assessments (eCOAs), ePatient Reported
Outcomes (ePROs), Clinician Reported Outcomes (ClinROs),
ePatient Diaries, Performance Outcomes (PerfOs) and Observer
Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 27: USA Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 28: USA 7-Year Perspective for ePRO, ePatient Diaries and
eCOA by End-Use - Percentage Breakdown of Value Revenues for
Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

CANADA
Table 29: Canada Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 30: Canada 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Solution Type - Percentage Breakdown of Value
Revenues for EClinical Outcome Assessments (eCOAs), ePatient
Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 31: Canada Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: Canada 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by End-Use - Percentage Breakdown of Value Revenues
for Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

JAPAN
Table 33: Japan Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 34: Japan 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Solution Type - Percentage Breakdown of Value
Revenues for EClinical Outcome Assessments (eCOAs), ePatient
Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 35: Japan Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 36: Japan 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by End-Use - Percentage Breakdown of Value Revenues
for Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

CHINA
Table 37: China Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 38: China 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Solution Type - Percentage Breakdown of Value
Revenues for EClinical Outcome Assessments (eCOAs), ePatient
Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 39: China Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 40: China 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by End-Use - Percentage Breakdown of Value Revenues
for Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

EUROPE
Table 41: Europe Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 42: Europe 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Geographic Region - Percentage Breakdown of Value
Revenues for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2021 & 2027

Table 43: Europe Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Europe 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Solution Type - Percentage Breakdown of Value
Revenues for EClinical Outcome Assessments (eCOAs), ePatient
Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 45: Europe Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 46: Europe 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by End-Use - Percentage Breakdown of Value Revenues
for Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

FRANCE
Table 47: France Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 48: France 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Solution Type - Percentage Breakdown of Value
Revenues for EClinical Outcome Assessments (eCOAs), ePatient
Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 49: France Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: France 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by End-Use - Percentage Breakdown of Value Revenues
for Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

GERMANY
Table 51: Germany Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 52: Germany 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Solution Type - Percentage Breakdown of Value
Revenues for EClinical Outcome Assessments (eCOAs), ePatient
Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 53: Germany Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 54: Germany 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by End-Use - Percentage Breakdown of Value Revenues
for Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

ITALY
Table 55: Italy Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Italy 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by Solution Type - Percentage Breakdown of Value
Revenues for EClinical Outcome Assessments (eCOAs), ePatient
Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 57: Italy Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 58: Italy 7-Year Perspective for ePRO, ePatient Diaries
and eCOA by End-Use - Percentage Breakdown of Value Revenues
for Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

UNITED KINGDOM
Table 59: UK Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 60: UK 7-Year Perspective for ePRO, ePatient Diaries and
eCOA by Solution Type - Percentage Breakdown of Value Revenues
for EClinical Outcome Assessments (eCOAs), ePatient Reported
Outcomes (ePROs), Clinician Reported Outcomes (ClinROs),
ePatient Diaries, Performance Outcomes (PerfOs) and Observer
Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 61: UK Current & Future Analysis for ePRO, ePatient
Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract
Research Organizations (CROs), Hospitals, Academic Institutes
and Other End-Uses - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: UK 7-Year Perspective for ePRO, ePatient Diaries and
eCOA by End-Use - Percentage Breakdown of Value Revenues for
Clinical Trial Sponsors, Contract Research Organizations
(CROs), Hospitals, Academic Institutes and Other End-Uses for
the Years 2021 & 2027

REST OF EUROPE
Table 63: Rest of Europe Current & Future Analysis for ePRO,
ePatient Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 64: Rest of Europe 7-Year Perspective for ePRO, ePatient
Diaries and eCOA by Solution Type - Percentage Breakdown of
Value Revenues for EClinical Outcome Assessments (eCOAs),
ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 65: Rest of Europe Current & Future Analysis for ePRO,
ePatient Diaries and eCOA by End-Use - Clinical Trial Sponsors,
Contract Research Organizations (CROs), Hospitals, Academic
Institutes and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 66: Rest of Europe 7-Year Perspective for ePRO, ePatient
Diaries and eCOA by End-Use - Percentage Breakdown of Value
Revenues for Clinical Trial Sponsors, Contract Research
Organizations (CROs), Hospitals, Academic Institutes and Other
End-Uses for the Years 2021 & 2027

ASIA-PACIFIC
Table 67: Asia-Pacific Current & Future Analysis for ePRO,
ePatient Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Asia-Pacific 7-Year Perspective for ePRO, ePatient
Diaries and eCOA by Solution Type - Percentage Breakdown of
Value Revenues for EClinical Outcome Assessments (eCOAs),
ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 69: Asia-Pacific Current & Future Analysis for ePRO,
ePatient Diaries and eCOA by End-Use - Clinical Trial Sponsors,
Contract Research Organizations (CROs), Hospitals, Academic
Institutes and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 70: Asia-Pacific 7-Year Perspective for ePRO, ePatient
Diaries and eCOA by End-Use - Percentage Breakdown of Value
Revenues for Clinical Trial Sponsors, Contract Research
Organizations (CROs), Hospitals, Academic Institutes and Other
End-Uses for the Years 2021 & 2027

REST OF WORLD
Table 71: Rest of World Current & Future Analysis for ePRO,
ePatient Diaries and eCOA by Solution Type - EClinical Outcome
Assessments (eCOAs), ePatient Reported Outcomes (ePROs),
Clinician Reported Outcomes (ClinROs), ePatient Diaries,
Performance Outcomes (PerfOs) and Observer Reported Outcomes
(ObsROs) - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 72: Rest of World 7-Year Perspective for ePRO, ePatient
Diaries and eCOA by Solution Type - Percentage Breakdown of
Value Revenues for EClinical Outcome Assessments (eCOAs),
ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes
(ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and
Observer Reported Outcomes (ObsROs) for the Years 2021 & 2027

Table 73: Rest of World Current & Future Analysis for ePRO,
ePatient Diaries and eCOA by End-Use - Clinical Trial Sponsors,
Contract Research Organizations (CROs), Hospitals, Academic
Institutes and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 74: Rest of World 7-Year Perspective for ePRO, ePatient
Diaries and eCOA by End-Use - Percentage Breakdown of Value
Revenues for Clinical Trial Sponsors, Contract Research
Organizations (CROs), Hospitals, Academic Institutes and Other
End-Uses for the Years 2021 & 2027

IV. COMPETITION
Total Companies Profiled: 49
Read the full report: https://www.reportlinker.com/p05956727/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting